Kisspeptin

Kisspeptin is a reproductive signaling peptide studied for sexual health, hormone signaling, fertility biology, and sexual desire pathways.

In simple terms, kisspeptin helps tell the brain when to activate the body's reproductive hormone system. It works upstream by signaling the release of GnRH, gonadotropin-releasing hormone. GnRH then tells the pituitary gland to release LH and FSH, two hormones that help regulate testosterone, estrogen, ovulation, sperm production, fertility, and sexual function.

The simple way to understand Kisspeptin:

Kisspeptin is a master signal for the reproductive hormone system.

In men, kisspeptin is studied for its ability to stimulate LH release, which can support the body's own testosterone production pathway.

In women, kisspeptin is studied for ovulation signaling, reproductive hormone regulation, fertility treatment research, and sexual desire brain processing.

In practical human terms, Kisspeptin is researched for:

• Sexual desire pathways

• Reproductive hormone signaling

• GnRH activation

• LH and FSH release

• Testosterone pathway support in men

• Ovulation and fertility signaling in women

• Sexual arousal brain processing

• Penile tumescence research in men with low sexual desire

• IVF and oocyte maturation research

Kisspeptin is not testosterone. It is not Viagra. It is not a stimulant. It is not a simple libido booster. It works higher up in the hormonal command chain by helping activate the brain-to-pituitary-to-gonadal signaling system.

The most accurate framing is that Kisspeptin is a reproductive hormone signaling peptide studied for GnRH activation, LH and FSH release, testosterone pathway support, fertility biology, and sexual desire-related brain signaling.

Kisspeptin refers to a family of peptides produced from the KISS1 gene. It was originally identified in cancer metastasis research, which is why it is also called metastin. Later research established kisspeptin as a critical regulator of the hypothalamic-pituitary-gonadal axis, the hormonal system that controls reproductive function.

Kisspeptin acts through the kisspeptin receptor, also known as KISS1R or GPR54. This receptor is highly important for puberty, fertility, reproductive hormone signaling, and normal sexual development. Loss-of-function mutations in the kisspeptin receptor pathway are associated with impaired puberty and reproductive dysfunction, while activating mutations can be linked with early puberty.

The main endocrine action of kisspeptin is stimulation of GnRH neurons in the hypothalamus. GnRH then stimulates the pituitary gland to release luteinizing hormone, LH, and follicle-stimulating hormone, FSH. LH and FSH then act on the gonads, meaning the testes in men and ovaries in women.

In men, LH stimulates Leydig cells in the testes to produce testosterone. FSH supports sperm production through its action on Sertoli cells. Because kisspeptin can increase GnRH and LH signaling, it is studied for testosterone pathway support and male reproductive hormone regulation.

In women, LH and FSH regulate ovarian follicle development, ovulation, estrogen production, progesterone signaling, and fertility. Kisspeptin is studied in women because it sits above these reproductive processes and can help trigger the hormone cascade involved in ovulation and reproductive function.

Within Sexual Health, Kisspeptin belongs on the reproductive hormone signaling and sexual desire side of the category. It is different from PT-141, which acts through melanocortin receptor pathways related to sexual desire. Kisspeptin acts through reproductive neuroendocrine signaling and also appears to influence sexual and emotional brain processing.

Human Evidence

Kisspeptin has meaningful human research, especially in reproductive endocrinology.

A clinical study in healthy men showed that kisspeptin-10 potently stimulated LH secretion, increased LH pulse frequency, increased LH pulse size, and increased testosterone during continuous infusion. This supports kisspeptin's role as an upstream activator of the male reproductive hormone axis.

Another proof-of-concept study in hypotestosteronaemic men with type 2 diabetes found that kisspeptin-10 increased LH pulse frequency and LH secretion, with associated increases in serum testosterone. This supports interest in kisspeptin agonists as potential tools for enhancing endogenous testosterone secretion in specific central hypogonadism research contexts.

Kisspeptin has also been studied in men with hypoactive sexual desire disorder, also called HSDD. In a randomized clinical trial of 32 men with HSDD, kisspeptin-54 administration modulated sexual brain processing, increased penile tumescence in response to sexual stimuli, and improved behavioral measures of sexual desire and arousal. This suggests kisspeptin may influence both hormonal and brain-based aspects of sexual function.

Kisspeptin has also been studied in women with HSDD. In a randomized clinical trial of 32 premenopausal women, kisspeptin-54 modulated sexual and attraction brain processing and was well tolerated with no reported adverse effects in that study. These results support interest in kisspeptin as a sexual desire research compound, but they do not make it an approved treatment for low libido.

Kisspeptin also has fertility research relevance. Human IVF research has evaluated kisspeptin-54 as a physiological trigger for oocyte maturation. Studies suggest kisspeptin can induce oocyte maturation in women undergoing IVF treatment and may be useful in specific fertility-treatment contexts, especially where reducing ovarian hyperstimulation risk is important. This is fertility medicine research, not general wellness use.

The strongest research themes for Kisspeptin are:

• GnRH activation

• LH and FSH release

• Testosterone pathway support in men

• Ovulation signaling in women

• Puberty and reproductive-axis regulation

• Fertility and IVF trigger research

• Sexual desire brain processing

• Sexual arousal signaling

• Penile tumescence research in men with HSDD

• Attraction and erotic brain-processing research in women with HSDD

The evidence is strongest for kisspeptin's role in reproductive hormone signaling. The sexual desire research is promising but still early. Kisspeptin should not be described as a proven libido drug, testosterone replacement, erectile dysfunction treatment, infertility treatment, or hormone optimization therapy.

Kisspeptin should be presented as a reproductive endocrine research peptide, not as a casual sexual performance supplement.

Because kisspeptin acts high in the reproductive hormone axis, it can influence downstream hormonal systems including GnRH, LH, FSH, testosterone, estrogen, progesterone, ovulation, and fertility-related signaling. That means it should be treated as endocrine-active.

Potential concerns may include unwanted hormonal changes, effects on fertility signaling, menstrual-cycle effects, testosterone pathway changes, mood or sexual-behavior effects, injection or route-related risks, product purity concerns, peptide-related impurities, and unknown long-term safety in non-research use.

Special caution is relevant for people with hormone-sensitive cancers, pituitary or hypothalamic disorders, infertility treatment protocols, pregnancy, breastfeeding, endocrine disorders, polycystic ovary syndrome, prostate disease, testicular disease, ovarian disease, or anyone using hormone therapy.

From a regulatory standpoint, FDA lists Kisspeptin-10 among bulk drug substances that may present significant safety risks in compounding. FDA states that compounded drugs containing Kisspeptin-10 may pose immunogenicity risk for certain routes of administration and may have complexities related to peptide impurities and active pharmaceutical ingredient characterization. FDA also states it has no, or only limited, safety-related information for the proposed routes of administration and lacks sufficient information to know whether the drug would cause harm when administered to humans.

Kisspeptin is also prohibited in sport. The 2026 World Anti-Doping Agency Prohibited List includes kisspeptin and its agonist analogues under prohibited peptide hormones, growth factors, related substances, and mimetics. This matters for tested athletes, fighters, professional competitors, military athletes, and anyone subject to anti-doping rules.

Kisspeptin is a reproductive neuroendocrine peptide studied for GnRH activation, LH and FSH release, testosterone pathway support, ovulation signaling, fertility biology, IVF-related oocyte maturation research, sexual desire brain processing, sexual arousal signaling, and hypothalamic-pituitary-gonadal axis regulation.

Kisspeptin is best positioned as a sexual health and reproductive hormone signaling research peptide.

Its strongest practical relevance is the study of how the brain activates the reproductive hormone system, how LH and FSH regulate testosterone and fertility pathways, and how kisspeptin may influence sexual desire-related brain processing.

The most accurate framing is reproductive hormone signaling, fertility biology, and sexual desire research.

It should not be positioned as guaranteed libido enhancement, testosterone replacement, erectile dysfunction treatment, fertility treatment, hormone therapy, performance enhancement, bodybuilding support, anti-aging therapy, or disease treatment.